This article is part of a monthly column that considers the significance of recent Federal Trade Commission announcements about antitrust issues. In this installment, we discuss the FTC's complaint on PBMs' conduct around...more
10/3/2024
/ Administrative Complaints ,
Anti-Competitive ,
Article II ,
Drug Pricing ,
Due Process ,
Federal Trade Commission (FTC) ,
FTC Act ,
Healthcare ,
Manufacturers ,
Out-of-Pocket Expenses ,
Pharmaceutical Industry ,
Pharmacies ,
Pharmacy Benefit Manager (PBM) ,
Sherman Act